Condition: Parkinson's Disease · Sponsor: Genemagic Biosciences Co., Ltd
The objective of this study is to assess the safety of GM101 in participants with Parkinson's disease (PD)
This description comes directly from the study's public registry record.
Kaikai Li, Master · +86 159 0069 2632 · kaikaili@genemagicbio.com
Always discuss trial participation with your own doctor first.
| Xiangya Hospital, Central South University | Changsha, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07100171